Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease. The aim of prospective randomized study is to evaluate the effects of TCM Daoyin training on Individuals at-risk for COPD.
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. Early prevention and treatment of COPD is crucial, but there is a lack of specific interventions for individuals at-risk for COPD in clinical guidelines. The study focuses on individuals at-risk for COPD (COPD-SQ≥16, current lung function failed to meet diagnostic criteria for COPD but with manifestations of early airflow limitation). This is a two-group prospective, randomized, assessor-blinded trial, planning to enroll 60 participants (30 for TCM Daoyin intervention group receiving health education plus a TCM Daoyin training program, and 30 for health education control group only receiving health education). TCM Daoyin is a form of mind-body exercise with a profound philosophical foundation rooted in Chinese culture. Previous researches have provided some evidence of beneficial effects on TCM Daoyin for COPD patients with an established diagnosis, such as Liuzijue and Baduanjin. However, the evidences of TCM Daoyin on patients with early COPD is limited. The aim of prospective randomized study is to evaluate the effects of TCM Daoyin training on individuals at-risk of COPD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
60
The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
Health education is provided by doctor and nurse, including work, rest, diet and other basic programs.
Shanghai Qigong Research Institute
Shanghai, Shanghai Municipality, China
Changzheng Community Health Service Center of Putuo District, Shanghai
Shanghai, Shanghai Municipality, China
Lung function
Participants' lung function (FVC、FVC%、FEV1、FEV1%、FEV1/FVC) will be tested to identify air flow condition in both group.
Time frame: Change from Baseline lung function at 16 weeks
6-min walk distance(6MWD)
The 6MWD is a well-established field exercise test to assess the functional exercise capacity in COPD clinical trials.
Time frame: Change from Baseline 6MWD at 16 weeks
Immune function
Venous blood will be collect to detect immunity function (IL-6, IL-8, IL-10 and biomarkers).
Time frame: Change from Baseline immune function at 16 weeks
Depression, Anxiety and Stress Scale-21 item (DASS-21)
Questions focus on depressive, anxious and stress symptoms during the past 7 days, and higher cumulative scores indicate more severe depression, anxiety and stress. Subscale scores are calculated as the sum of the responses to the seven items from each subscale multiplied by 2. The cutoffs for depression, anxiety, and stress are \>9, \>7, and \>14, respectively.
Time frame: Change from Baseline DASS-21 at 16 weeks
St. George's Respiratory Questionnaire (SGRQ)
Quality of Life will be assessed by St. George's Respiratory Questionnaire (SGRQ). The SGRQ is a disease-specific measure of health status for use in COPD. It has a 0 - 100 score; 0 as low symptoms (feeling better) and 100 as high symptoms (feeling worse). A 4-unit change is the minimum clinically important difference.
Time frame: Change from Baseline SGRQ at 16 weeks
Adverse effects
During the intervention period, the doctors will ask specifically about, and record any adverse effect of the treatment that may have occurred.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 8 weeks
Adverse effects
During the intervention period, the doctors will ask specifically about, and record any adverse effect of the treatment that may have occurred.
Time frame: 16 weeks